Cambium Bio Limited (ASX:CMB)

Market Cap	10.80M +120.7%
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	27.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,274
Average Volume	6,605
Open	0.3900
Previous Close	0.3950
Day's Range	0.3700 - 0.3950
52-Week Range	0.2000 - 0.6000
Beta	-0.15
RSI	41.52
Earnings Date	n/a

About Cambium Bio

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CMB